Chief Financial Officer · Viridian Therapeutics, Inc. (VRDN)

Seth Harmon

A named executive officer of Viridian Therapeutics in every fiscal year CompBrief holds from FY2023 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$2,642,779

FY2024: $770,659

4th of 5 named executive officers at Viridian Therapeutics by FY2025 total.

5 named officers on file for Viridian Therapeutics, FY2025

See an example →

What this number hides

The filing gives the total. Viridian Therapeutics’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how Viridian Therapeutics’s whole pay program stands against its peers

  • Viridian Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VRDN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 17, 2026 (DEF 14A).

Free

Get Seth Harmon’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Seth Harmon and every company like it: Velarion Intel, free for 3 days, no card →

Seth Harmon compensation by year

Viridian Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Viridian Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024FY2025
Salary$241,427$419,600$480,000
Bonus$372,200$123,000$0
Stock awards$0$0$361,230
Option awards$5,930,567$0$1,495,898
Non-equity incentive$0$218,192$288,000
Pension and deferred compensation$0$0$0
All other$4,332$9,867$17,651
Total$6,548,526$770,659$2,642,779

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Viridian Therapeutics, Inc. DEF 14A filed April 17, 2026, accession 0001193125-26-160344, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Viridian Therapeutics, Inc. filed document, accession 0001193125-26-160344. Every figure is read from that document and cited to the page and table it appears in. Filed April 17, 2026.

$6.5M
$771K
$2.6M
FY23
FY24
FY25
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU25,068$780,116—
Option61,980—$24.50
Option122,206—$14.41
Option129,375—$13.76

Per the Outstanding Equity Awards at Fiscal Year-End table in Viridian Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Change-in-control & termination

estimated payments Viridian Therapeutics discloses, by trigger · FY2025
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Involuntary termination without cause$480,000$289,625$39,659$809,284
Resignation for good reason, no change in control$480,000$289,625$39,659$809,284
Change in control and involuntary termination$672,000$5,478,436$39,659$6,190,095
Change in control and resignation for good reason$672,000$5,478,436$39,659$6,190,095

Per the Potential Payments Upon Termination or Change in Control table in Viridian Therapeutics, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.

Viridian Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Stephen MahoneyPresident, Chief Executive Officer$6,776,249
Radhika TripuraneniChief Medical Officer$4,080,466
Thomas BeethamChief Operating Officer$3,761,182
Seth Harmon · this pageChief Financial Officer$2,642,779
Jennifer TousignantChief Legal Officer$2,351,915

Seth Harmon's compensation dossier, Viridian Therapeutics

You have read Seth Harmon's totals and holdings. The dossier adds each equity grant Viridian Therapeutics disclosed for Seth Harmon and Viridian Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full Viridian Therapeutics compensation record

free company brief

This page is one person within Viridian Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Viridian Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Viridian Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Viridian Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order VRDN

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Seth Harmon's compensation dossier